discovered a new factor in the pathology of Parkinson's disease, which in the future may serve as a target for developing new ...

discovered a new factor in the pathology of Parkinson's disease, which in the future may serve as a target for developing new ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

offering a new therapeutic ... A Risky Business: Why Do Some Parkinson's Disease Treatments Affect Decision Making? Sep. 24, 2024 — Parkinson's disease, a debilitating nervous system disorder ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's treatment ...

Nir Giladi from TAU’s Faculty of Medical and Health Sciences and the Tel Aviv Sourasky Medical Center, as well as other researchers from TAU and the University of Haifa. The study was backed by the ...

Out-of-pocket costs for drugs for neurologic diseases such as MS, Parkinson's and Alzheimer's disease are climbing sharply, ...

There’s still a lot we don’t know about how Parkinson’s disease develops. But one lifestyle intervention already has strong evidence behind it.

People with multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, and that amount soared to $2,378 annually in 2021, according to a new study. The study  examined the ...

Certain cancers and Parkinson's disease are especially difficult to treat ... initiative with a leading pharmaceutical ...

offering a new therapeutic target for Parkinson's and other movement ... Some Diabetes Drugs Tied to Lower Risk of Dementia, Parkinson's Disease Sep. 18, 2024 — A class of drugs for diabetes may ...